Anti-CD20 mAB
Phase 2Small molecule
Anti-CD20 mAB is one of 40 small molecule programs targeting Secondary Progressive Multiple Sclerosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Secondary Progressive Multiple Sclerosis
#DrugCompanyPhaseTrials
1Spikevax
ModernaApproved
BAF312
NovartisApproved
Rilutek
AAzurity Pharmaceuticals
Approved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Midamor
PPadagis LLC
Approved
Glucophage
EMD SeronoApproved
Novantrone
EMD SeronoApproved
Medrol
PfizerPhase 3
Tysabri
BiogenPhase 3
Rhapsido
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-CD20 mAB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- KKyverna Therapeutics